These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27237449)

  • 1. Hypertrophic lupus erythematosus successfully treated with hydroxychloroquine.
    Yoshimoto N; Shinkuma S; Ujiie H; Nomura T; Fujita Y; Abe R; Shimizu H
    J Dermatol; 2017 Mar; 44(3):e48-e49. PubMed ID: 27237449
    [No Abstract]   [Full Text] [Related]  

  • 2. Beneficial effect of hydroxychloroquine on cutaneous vasculitis in a Japanese patient with systemic lupus erythematosus.
    Kibune N; Shimomura Y; Hasegawa A; Saeki T; Umemori Y; Abe R
    J Dermatol; 2017 Apr; 44(4):e52-e53. PubMed ID: 27569899
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
    Kishi C; Motegi SI; Yasuda M; Ishikawa O
    J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
    [No Abstract]   [Full Text] [Related]  

  • 4. Vesico-bullous subacute cutaneous lupus erythematosus--an uncommon entity successfully treated with dapsone and hydroxychloroquine.
    Pinto-Almeida T; Sanches M; Alves R; Selores M
    Dermatol Online J; 2012 Aug; 18(8):13. PubMed ID: 22948063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 10. Hydroxychloroquine].
    Yokogawa N
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2960-5. PubMed ID: 22175138
    [No Abstract]   [Full Text] [Related]  

  • 6. Chilblain lupus erythematosus.
    Patel S; Hardo F
    BMJ Case Rep; 2013 Nov; 2013():. PubMed ID: 24285807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y; Arai S; Eto H; Kishimoto M; Okada M
    J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plaque-like Cutaneous Lupus Mucinosis as the First Sign of Systemic Lupus Erythematosus.
    Gao M; Sheng N; Yang X; Jiang Y
    Acta Derm Venereol; 2020 Feb; 100(4):adv00048. PubMed ID: 31774542
    [No Abstract]   [Full Text] [Related]  

  • 9. Variable presentations of subacute cutaneous lupus erythematosus.
    Balma-Mena A; Ho N
    J Cutan Med Surg; 2010; 14(4):195-8. PubMed ID: 20642992
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating results of an interferon-γ release assay in patients with autoimmune disease who are taking hydroxychloroquine.
    Gaffney RG; Werth VP
    J Am Acad Dermatol; 2019 Apr; 80(4):1162-1164. PubMed ID: 30582995
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of hydroxychloroquine on cutaneous lupus erythematosus in a Japanese girl.
    Yamamoto T; Hiraiwa T
    J Dermatol; 2014 Apr; 41(4):357-9. PubMed ID: 24617496
    [No Abstract]   [Full Text] [Related]  

  • 13. Dramatic effect of hydroxychloroquine on lupus alopecia.
    Igari S; Yamamoto T
    J Dermatol; 2018 Feb; 45(2):194-197. PubMed ID: 29068087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
    Callen JP
    Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous manifestations of connective tissue disease.
    McCammack E; Haggstrom AN
    Adolesc Med State Art Rev; 2011 Apr; 22(1):35-53. PubMed ID: 21815443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment.
    Mauldin EA; Morris DO; Brown DC; Casal ML
    Vet Dermatol; 2010 Aug; 21(4):373-82. PubMed ID: 20374572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
    Avgerinou G; Papafragkaki DK; Nasiopoulou A; Arapaki A; Katsambas A; Stavropoulos PG
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):762-7. PubMed ID: 21707772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
    Pelle MT; Callen JP
    Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ototoxicity due to hydroxychloroquine: report of two cases.
    Johansen PB; Gran JT
    Clin Exp Rheumatol; 1998; 16(4):472-4. PubMed ID: 9706431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.